Approaching an age of reason with antiplatelet therapy

被引：3

作者：

Ajani, Andrew E. ^{[1
]}

Lefkovits, Jeffrey ^{[1
]}

机构：

[1] Royal Melbourne Hosp, Dept Cardiol, Parkville, Vic 3050, Australia

来源：

LANCET | 2008年 / 371卷 / 9621期

关键词：

D O I：

10.1016/S0140-6736(08)60573-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1315 / 1316

页数：2

共 11 条

[1] King Spencer B 3rd, 2008, J Am Coll Cardiol, V51, P172, DOI 10.1016/j.jacc.2007.10.002
[2] Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions -: Appropriateness of including bleeding as a component of a quadruple end point
Ndrepepa, Gjin
Berger, Peter B.
Mehilli, Julinda
Seyfarth, Melchior
Neumann, Franz-Josef
Schoemig, Albert
Kastrati, Adnan
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (07) : 690 - 697
[3] Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
Niitsu, Y
Jakubowski, JA
Sugidachi, A
Asai, F
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) : 184 - 194
[4] Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Payne, Christopher D.
Li, Ying Grace
Small, David S.
Ernest, C. Steven, II
Farid, Nagy A.
Jakubowski, Joseph A.
Brandt, John T.
Salazar, Daniel E.
Winters, Kenneth J.
[J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) : 555 - 562
[5] Assessment of bleeding events in clinical trials - Proposal of a new classification
Serebrulany, Victor L.
Atar, Dan
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (02) : 288 - 290
[6] Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Wallentin, Lars
Varenhorst, Christoph
James, Stefan
Erlinge, David
Braun, Oscar Oe
Jakubowski, Joseph A.
Sugidachi, Atsuhiro
Winters, Kenneth J.
Siegbahn, Agneta
[J]. EUROPEAN HEART JOURNAL, 2008, 29 (01) : 21 - 30
[7] Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Wiviott, Stephen D.
Braunwald, Eugene
McCabe, Carolyn H.
Horvath, Ivan
Keltai, Matyas
Herrman, Jean-Paul R.
Van de Werf, Frans
Downey, William E.
Scirica, Benjamin M.
Murphy, Sabina A.
Antman, Elliott M.
[J]. LANCET, 2008, 371 (9621) : 1353 - 1363
[8] Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Wiviott, Stephen D.
Trenk, Dietmar
Frelinger, Andrew L.
O'Donoghue, Michelle
Neumann, Franz-Josef
Michelson, Alan D.
Angiolillo, Dominick J.
Hod, Hanoch
Montalescot, Gilles
Miller, Debra L.
Jakubowski, Joseph A.
Cairns, Richard
Murphy, Sabina A.
McCabe, Carolyn H.
Antman, Elliott M.
Braunwald, Eugene
[J]. CIRCULATION, 2007, 116 (25) : 2923 - 2932
[9] Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, Stephen D.
Braunwald, Eugene
McCabe, Carolyn H.
Montalescot, Gilles
Ruzyllo, Witold
Gottlieb, Shmuel
Neumann, Franz-Joseph
Ardissino, Diego
De Servi, Stefano
Murphy, Sabina A.
Riesmeyer, Jeffrey
Weerakkody, Govinda
Gibson, C. Michael
Antman, Elliott M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) : 2001 - 2015
[10] Yusuf S, 2006, NEW ENGL J MED, V354, P1464

← 1 2 →